Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?
Yes price
82¢
No price
18¢
Bid 82¢
Ask 90¢
Mid 86¢
OI $366
About this market: Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028? is currently priced at 82¢ for Yes and 18¢ for No on kalshi, in the other category. It resolves on Jan 1, 2028 (13mo from now). Daily volume is around $1K. No matched market was found on the other platform yet.
Cross-Platform Prices
More other markets
All other markets →
polymarket
Will Jesus Christ return before 2027?
<1¢
$67.1M
kalshi
More tech layoffs in 2026 than in 2025?
99¢
$31.5M
kalshi
Will the U.S. confirm that aliens exist before 2027?
2¢
$30.8M
polymarket
Hantavirus pandemic in 2026?
1¢
$19.1M
kalshi
Will "SAVE Act" (H.R. 22) becomes law before Jan 4, 2027?
2¢
$16.0M
kalshi
Carlos Alcaraz wins
95¢
$13.7M
kalshi
Barcelona wins
72¢
$10.9M
kalshi
Taylor Fritz wins
4¢
$9.7M